You are here: Home » Companies » News
Business Standard

Jubilant Life Sciences arm recalls 12,960 bottles of esophagitis drug in US

Reason for recall is "Discoloration: expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets"

Press Trust of India  |  New Delhi 

Drugs, Pharma, medicine
Representative image

Pharmaceuticals Inc is recalling 12,960 bottles of delayed-release tablets from the American market, as per a report of the US health regulator.

The tablets are used for the short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD).

Salisbury-based Pharmaceuticals Inc is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of Noida-based

Pharmaceuticals Inc is recalling 12,960 bottles of the tablets in the strength of 40 mg, manufactured by Jubilant Generics Ltd at its Roorkee plant, the Enforcement Report of the US Food and Drug Adminstration (USFDA) said.

The reason for recall is "Discoloration: expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets".

In October 2018, Jubilant Cadista Pharmaceuticals had said it was recalling over 1.58 lakh bottles of delayed-release tablets, manufactured by Jubilant Generics Ltd at its Roorkee plant, from the US and Puerto Rico.

The ongoing voluntary nationwide recall in the US is a class II recall, the report added.

As per the USFDA, a class II recall is initiated in a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

First Published: Sun, April 14 2019. 12:03 IST
RECOMMENDED FOR YOU